Research & Trials

Drug development programs.

We are leading the sector in advancing the potential of DMT based therapy, using rigorous, comprehensive and innovative methods.

SPL026
Injectable DMT
Exploring the potential of SPL026 with talk therapy to treat Major Depressive Disorder.
SPL028
Prolonged DMT Series
An injectable formulation of deuterated DMT designed to deliver a more prolonged psychedelic experience.
SPL029
Oral DMT series
An oral formulation of a tryptamine to offer an alternative way to deliver the treatment to patients in clinic.
SPL801
Oral 6-hydroxynorketamine
An oral formulation of 6-HNK, a ketamine metabolite, was shown in early preclinical studies to have signs of rapid antidepressant effects with an improved side effect profile to ketamine.

Our Pipeline

Our current progress across our R&D programs

Our lead program

Part A (Phase 1)

Status: Completed 

No. of participants: 32

Type of participants: Psychedelic naive healthy volunteers

Outcomes: safety, tolerability, pharmacokinetics and pharmacodynamics

Location: Hammersmith Medical Research, London

Part B (Phase IIA)

Status: Recruiting

Types of participants: Patients with moderate/ severe Major Depressive Disorder

No. of participants: 42

Outcomes: safety, tolerability, pharmacokinetics and pharmacodynamics

Location: Hammersmith Medical Research, London and MAC Clinical Research, Liverpool

Summary

We are conducting a double-blind, placebo-controlled Phase I/IIa of SPL026 in combination with therapy to explore the safety, tolerability and efficacy of DMT assisted therapy.

Drug: SPL026, Placebo

Clinical trial ID: NCT04673383

Indication: Major Depressive Disorder

Pipeline programs

We are developing a pipeline of tryptamine based psychedelic drug candidates.

Our pipeline offers alternative drug formulations and drug profiles, providing options that could potentially suit different patient preferences and better target alternative health indications.

Using our proprietary deuterium enriching technology (replacing hydrogen atoms with heavier hydrogen atoms), we are able to alter the pharmacokinetic profile (how a drug travels through the body) of tryptamine drugs. By re-engineering tryptamine based compounds, we are able to develop a drug pipeline that potentially offers the ability to:

  • vary the duration of a psychedelic experience
  • establish alternative formulations

Partners

DMT therapist training

Overview

To support our clinical programs, we are developing a training program for therapists to help the delivery of DMT focused therapy protocols.

Designed by experts

Our training program has been designed in collaboration with leading experts of psychedelic therapy methods.

Multi-method approach

Our program uses multiple methods including theory, experimental learning and observational work, ensuring therapists feel comfortable and empowered to deliver the protocol in a clinical trial setting.

Recruitment process

We are actively recruiting therapists and registering the interest of individuals interested in our DMT therapy training. Completion of the therapy training will enable you to be eligible to participate as a therapist in our future clinical trials.

 

To find out more, or to register your interest in upcoming therapist training programs, please email Dr Graham Campbell at:

graham.campbell@smallpharma.co.uk

Stay up to date with our breakthrough R&D programs

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: